ID   Daoy
AC   CVCL_1167
AS   CVCL_7903
SY   DAOY; D324 Med; D-324 Med; D324 MED; D-324MED; D324
DR   BTO; BTO:0004328
DR   CLO; CLO_0002699
DR   EFO; EFO_0005698
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-186
DR   BCRJ; 0325
DR   BioGRID_ORCS_Cell_line; 687
DR   BioSample; SAMN03470909
DR   BioSample; SAMN10988097
DR   cancercelllines; CVCL_1167
DR   CCRID; 1101HUM-PUMC000218
DR   CCRID; 3101HUMSCSP509
DR   Cell_Model_Passport; SIDM00887
DR   ChEMBL-Cells; CHEMBL3308510
DR   ChEMBL-Targets; CHEMBL612519
DR   CLS; 305053
DR   Cosmic; 687773
DR   Cosmic; 906833
DR   Cosmic; 923654
DR   Cosmic; 973262
DR   Cosmic; 974281
DR   Cosmic; 975027
DR   Cosmic; 1404441
DR   Cosmic; 1995383
DR   Cosmic; 2362649
DR   Cosmic; 2731177
DR   Cosmic-CLP; 906833
DR   DepMap; ACH-000211
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS055ILX
DR   ENCODE; ENCBS812KQP
DR   GDSC; 906833
DR   GEO; GSM482332
DR   GEO; GSM886972
DR   GEO; GSM888041
DR   GEO; GSM919361
DR   GEO; GSM1669725
DR   GEO; GSM1938719
DR   IARC_TP53; 480
DR   KCB; KCB 2010203YJ
DR   LiGeA; CCLE_339
DR   LINCS_LDP; LCL-1576
DR   Lonza; 1438
DR   NCBI_Iran; C519
DR   PharmacoDB; Daoy_282_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1167
DR   PubChem_Cell_line; CVCL_1167
DR   Wikidata; Q29511023
RX   DOI=10.1007/0-306-46861-1_11;
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=1822845;
RX   PubMed=2993532;
RX   PubMed=12973738;
RX   PubMed=18773455;
RX   PubMed=20164919;
RX   PubMed=20847082;
RX   PubMed=22343310;
RX   PubMed=22460905;
RX   PubMed=22723427;
RX   PubMed=24297863;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=27498314;
RX   PubMed=27812533;
RX   PubMed=29900115;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31346954;
RX   PubMed=31963405;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/DAOY_(biology)
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/d/cell-lines-detail-566.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 33.6 hours (Note=At 48th passage) (PubMed=2993532); 32 +- 1.5 hours (PubMed=31346954); 34 hours (ATCC=HTB-186).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Homozygous (PubMed=22343310; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.45%; Native American=0%; East Asian, North=1.54%; East Asian, South=0%; South Asian=1.1%; European, North=64.36%; European, South=32.54% (PubMed=30894373).
CC   Derived from site: In situ; Brain, posterior fossa; UBERON=UBERON_0008788.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 13,14
ST   D16S539: 10
ST   D18S51: 12
ST   D19S433: 14,14.2 (CCRID)
ST   D19S433: 14.2 (PubMed=25877200)
ST   D21S11: 29,31.2
ST   D2S1338: 16,17
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 8,10
ST   D8S1179: 13,15
ST   FGA: 23
ST   Penta D: 10,13
ST   Penta E: 7,11
ST   TH01: 9
ST   TPOX: 8,10
ST   vWA: 14,20
DI   NCIt; C129442; Medulloblastoma, SHH-activated, TP53-mutant
DI   ORDO; Orphanet_616; Medulloblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   4Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 42
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994).
//
RX   PubMed=1822845;
RA   Wikstrand C.J., Friedman H.S., Bigner D.D.;
RT   "Medulloblastoma cell-substrate interaction in vitro.";
RL   Invasion Metastasis 11:310-324(1991).
//
RX   PubMed=2993532; DOI=10.1097/00005072-198509000-00003;
RA   Jacobsen P.F., Jenkyn D.J., Papadimitriou J.M.;
RT   "Establishment of a human medulloblastoma cell line and its
RT   heterotransplantation into nude mice.";
RL   J. Neuropathol. Exp. Neurol. 44:472-485(1985).
//
RX   PubMed=12973738; DOI=10.1002/pmic.200300460;
RA   Peyrl A., Krapfenbauer K., Slavc I., Yang J.-W., Strobel T., Lubec G.;
RT   "Protein profiles of medulloblastoma cell lines DAOY and D283:
RT   identification of tumor-related proteins and principles.";
RL   Proteomics 3:1781-1800(2003).
//
RX   PubMed=18773455; DOI=10.1002/cyto.a.20633;
RA   Srivastava V.K., Nalbantoglu J.;
RT   "Flow cytometric characterization of the DAOY medulloblastoma cell
RT   line for the cancer stem-like phenotype.";
RL   Cytometry A 73:940-948(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20847082; DOI=10.1093/neuonc/noq091;
RA   Teider N., Scott D.K., Neiss A., Weeraratne S.D., Amani V.M., Wang Y.-F.,
RA   Marquez V.E., Cho Y.-J., Pomeroy S.L.;
RT   "Neuralized1 causes apoptosis and downregulates Notch target genes in
RT   medulloblastoma.";
RL   Neuro-oncol. 12:1244-1256(2010).
//
RX   PubMed=22343310; DOI=10.1016/j.neulet.2012.02.022;
RA   Ghassemifar S., Mendrysa S.M.;
RT   "MDM2 antagonism by nutlin-3 induces death in human medulloblastoma
RT   cells.";
RL   Neurosci. Lett. 513:106-110(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22723427; DOI=10.1093/neuonc/nos130;
RA   Sikkema A.H., den Dunnen W.F.A., Hulleman E., van Vuurden D.G.,
RA   Garcia-Manero G., Yang H., Scherpen F.J.G., Kampen K.R., Hoving E.W.,
RA   Kamps W.A., Diks S.H., Peppelenbosch M.P., de Bont E.S.J.M.;
RT   "EphB2 activity plays a pivotal role in pediatric medulloblastoma cell
RT   adhesion and invasion.";
RL   Neuro-oncol. 14:1125-1135(2012).
//
RX   PubMed=24297863; DOI=10.1158/1078-0432.CCR-13-2281;
RA   Bandopadhayay P., Bergthold G., Nguyen B., Schubert S., Gholamin S.,
RA   Tang Y.-J., Bolin S., Schumacher S.E., Zeid R., Masoud S., Yu F.-R.,
RA   Vue N., Gibson W.J., Paolella B.R., Mitra S.S., Cheshier S.H., Qi J.,
RA   Liu K.-W., Wechsler-Reya R.J., Weiss W.A., Swartling F.J., Kieran M.W.,
RA   Bradner J.E., Beroukhim R., Cho Y.-J.;
RT   "BET bromodomain inhibition of MYC-amplified medulloblastoma.";
RL   Clin. Cancer Res. 20:912-925(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27498314; DOI=10.1016/j.jbiotec.2016.07.028;
RA   Ivanov D.P., Coyle B., Walker D.A., Grabowska A.M.;
RT   "In vitro models of medulloblastoma: choosing the right tool for the
RT   job.";
RL   J. Biotechnol. 236:10-25(2016).
//
RX   PubMed=27812533; DOI=10.1016/j.dib.2016.10.004;
RA   Ivanov D.P., Walker D.A., Coyle B., Grabowska A.M.;
RT   "Data on the number and frequency of scientific literature citations
RT   for established medulloblastoma cell lines.";
RL   Data Brief 9:696-698(2016).
//
RX   PubMed=29900115; DOI=10.1016/j.euprot.2016.03.015;
RA   Martelli C., D'Angelo L., Barba M., Baranzini M., Inserra I.,
RA   Iavarone F., Vincenzoni F., Tamburrini G., Massimi L., Di Rocco C.,
RA   Caldarelli M., Messana I., Michetti F., Castagnola M., Lattanzi W.,
RA   Desiderio C.;
RT   "Top-down proteomic characterization of DAOY medulloblastoma tumor
RT   cell line.";
RL   EuPA Open Proteomics 12:13-21(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31346954; DOI=10.1007/s10616-019-00332-3;
RA   Bonfim Silva R., Salomao K.B., de Andrade Pimentel T.V.C.,
RA   de Oliveira Menezes C.C.B., Palma P.V.B., Fontes A.M.;
RT   "Biological characterization of the UW402, UW473, ONS-76 and DAOY
RT   pediatric medulloblastoma cell lines.";
RL   Cytotechnology 71:893-903(2019).
//
RX   PubMed=31963405; DOI=10.3390/cancers12010226;
RA   Casciati A., Tanori M., Manczak R., Saada S., Tanno B., Giardullo P.,
RA   Porcu E., Rampazzo E., Persano L., Viola G., Dalmay C., Lalloue F.,
RA   Pothier A., Merla C., Mancuso M.;
RT   "Human medulloblastoma cell lines: investigating on cancer stem
RT   cell-like phenotype.";
RL   Cancers (Basel) 12:226.1-226.14(2020).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//